M&A / Deals Lilly, Gilead lead pharma’s M&A boom BioPharma DiveDeal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.Read full story pharminent May 8, 2026 (Last updated: May 10, 2026) BioPharma Dive Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapyNext: Pulsesight reports positive phase 1 data for PST611 in dry AMD Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
